Vasopressin Formulation Stability via Neutral pH and Polymers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of vasopressin suffer from poor long-term stability, leading to degradation issues that affect their efficacy in clinical applications.
Innovation Solution
A pharmaceutical composition comprising vasopressin or its pharmaceutically-acceptable salt in combination with a polymeric excipient, which reduces degradation by up to 10% over a week at 60°C, when stored with a buffer at acidic pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If vasopressin is stored in conventional formulations with acidic buffer, then the formulation maintains basic stability, but the vasopressin degrades significantly after long-term storage at elevated temperatures
Solution Approach 1:
The patent changes the pH parameter of the buffer system from acidic (pH 3-5) to neutral (pH 6-8). This parameter change fundamentally alters the stability profile of vasopressin, reducing degradation by 5-10% after one week at 60°C compared to conventional acidic formulations. The neutral pH environment better preserves the peptide structure while maintaining formulation stability.
Solution Approach 2:
The patent employs a composite formulation system combining multiple excipients including buffers (phosphate, citrate, acetate), stabilizers (human serum albumin, gelatin, polysorbate 80), and tonicity agents. This composite approach creates synergistic effects that protect vasopressin from degradation through multiple mechanisms simultaneously, enhancing overall formulation stability during long-term storage.
2Ease of manufacture
If vasopressin is formulated with conventional excipients, then the formulation is simple to manufacture, but the long-term stability is poor leading to degradation
Solution Approach 1:
The patent modifies key formulation parameters including pH (6-8), ionic strength, and excipient concentrations to achieve optimal stability. These parameter adjustments are implemented through standard pharmaceutical manufacturing processes, maintaining ease of manufacture while dramatically improving reliability and long-term stability of the vasopressin formulation.
Data Source
AI summary
Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.